Related Experiment Videos
Serum beta2-microglobulin level is a significant predictor of mortality in maintenance haemodialysis patients
Senji Okuno1, Eiji Ishimura, Kaori Kohno
1Kidney Center, Shirasagi Hospital, Japan.
Background:
Beta(2)-microglobulin (beta(2)-M) is recognized as a surrogate marker of middle-molecule uraemic toxins and is a key component in the genesis of dialysis-associated amyloidosis. Few studies have evaluated the association of beta(2)-M levels with clinical outcome in dialyzed patients.
Methods:
The prognostic implication of serum beta(2)-M levels for the survival of haemodialysis patients was examined in 490 prevalent haemodialysis patients (60.1 +/- 11.8 years, haemodialysis duration of 87.4 +/- 75.7 months, 288 males and 202 females; 24% diabetics). The patients were divided into two groups according to their serum beta(2)-M levels: lower beta(2)-M group (n = 245) with serum beta(2)-M <32.2 mg/L (the median serum beta(2)-M) and higher beta(2)-M group (n = 245) with that >or=32.2 mg/L.
Results:
During the follow-up period of 40 +/- 15 months, there were 91 all-cause deaths, and out of them, 36 were from cardiovascular diseases. Kaplan-Meier analysis revealed that all-cause mortality in the higher beta(2)-M group was significantly higher compared to that in the lower beta(2)-M group (P < 0.001). Multivariate Cox proportional hazards analyses showed that serum beta(2)-M level was a significant predictor for all-cause mortality (hazard ratio, 1.05; 95% CI, 1.01-1.08; P = 0.005), and for non-cardiovascular mortality (hazard ratio, 1.06; 95% CI, 1.02-1.10; P = 0.006), after adjustment for age, gender, haemodialysis duration, the presence of diabetes, serum albumin and serum C-reactive protein.
Conclusion:
These results demonstrate that the serum beta(2)-M level is a significant predictor of mortality in haemodialysis patients, independent of haemodialysis duration, diabetes, malnutrition and chronic inflammation, suggesting the clinical importance of lowering serum beta(2)-M in these patients.
Insights
High beta(2)-microglobulin (beta(2)-M) levels predict increased mortality in hemodialysis patients. Lowering beta(2)-M may improve survival for individuals undergoing dialysis.
Area of Science:
- Nephrology
- Clinical Biochemistry
Background:
- Beta(2)-microglobulin (beta(2)-M) is a marker for middle-molecule uremic toxins.
- It plays a role in dialysis-associated amyloidosis.
- Limited data exist on beta(2)-M and clinical outcomes in dialysis patients.
Purpose of the Study:
- To investigate the prognostic significance of serum beta(2)-M levels on survival in hemodialysis patients.
Main Methods:
- Examined 490 prevalent hemodialysis patients.
- Grouped patients into lower (<32.2 mg/L) and higher (>=32.2 mg/L) serum beta(2)-M groups.
- Utilized Kaplan-Meier analysis and multivariate Cox proportional hazards models.
Main Results:
- Higher beta(2)-M levels were associated with significantly higher all-cause mortality (P < 0.001).
- Serum beta(2)-M independently predicted all-cause mortality (HR, 1.05; P = 0.005).
- It also predicted non-cardiovascular mortality (HR, 1.06; P = 0.006) after adjustments.
Conclusions:
- Serum beta(2)-M level is a significant predictor of mortality in hemodialysis patients.
- This association is independent of duration, diabetes, malnutrition, and inflammation.
- Lowering serum beta(2)-M is clinically important for this patient group.
Related Concept Videos
Serum Studies: Renal Function Tests
Hemodialysis III: Nursing Management
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Hemodialysis II: Procedure and Complications
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate
Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...